Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways

Abstract

While advances in science and technology have increased options for treating breast cancer, current social trends have changed the way people deal with this disease. Women in the United States are no longer simply passive patients, but rather they are survivors, advocates and activists who are speaking up for themselves and speaking out for issues relevant to the treatment and prevention of breast cancer. As the discoveries of basic science have been translated to better clinical treatment, a new sense of hope has emerged. Quality of life now shares the spotlight with quantity of life as breast cancer has shifted from an acute to a chronic condition and as the numbers of long-term survivors increase. While this new population tends to have more optimistic expectations for survival, they are also expressing concerns about issues affecting their lives through and beyond treatment. These issues include, but are not limited to, such concerns as efficient and accurate diagnosis, the complexity of treatment decisions, access to quality cancer care, informed consent, privacy issues, availability of supportive care treatments, and effective communication skills, especially with their physicians. Survivors are also concerned about the impact of their disease on spouses and family, on fertility and sexuality issues, on their employment and (in the USA) insurability, and on their long-term survival. The identification of these increasing issues has given rise to a consumer movement that encourages a shift away from powerless victim to empowered survivor.

A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer

“…After two days of attachment, cells were treated for five days with hormones and/or inhibitors in experimental medium containing either 1% FCS supplemented medium or 10% dextrancoated charcoal treated FCS-medium (FCS DCC ) [32]. A crystal violet colorimetric assay was used as an indirect measure of cell number [37].…”

NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer*

“…Proliferation Assay-Cells (4 ϫ 10 4 CYB5R3 siRNA and control siRNA transfected) were seeded in quadruplicate and stained with crystal violet on day 6 as described by Lundholt et al (29). Briefly, the cells were washed in PBS, followed by incubation (10 min) in 5% crystal violet (Sigma-Aldrich) and 25% methanol.…”

Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance

“…Untreated controls were added similar amount of vehicle (ethanol or DMSO) as the treated cultures. Growth medium was replaced on day 3, and cell number determined on day 5 as previously described using a crystal violet colorimetric assay [31]. The obtained optical density (OD) for each sample was expressed as a relative value in percent of untreated control.…”